{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:03:42Z","timestamp":1792040622062,"version":"4.4.0"},"reference-count":38,"publisher":"American Society of Hematology","issue":"26","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,12,12]]},"abstract":"<jats:title>Key Points<\/jats:title><jats:p>Accurate GZL diagnosis remains challenging, with &gt;60% of patients with presumed GZL having the diagnosis reclassified on consensus review. Treatment with DLBCL-based therapy appears most effective for GZL (including R-CHOP); however, new therapies are needed to improve outcomes.<\/jats:p>","DOI":"10.1182\/bloodadvances.2017009472","type":"journal-article","created":{"date-parts":[[2017,12,12]],"date-time":"2017-12-12T01:40:25Z","timestamp":1513042825000},"page":"2600-2609","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":77,"title":["Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL"],"prefix":"10.1182","volume":"1","author":[{"given":"Monika","family":"Pilichowska","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Tufts Medical Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Pittaluga","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A.","family":"Ferry","sequence":"additional","affiliation":[{"name":"Department of Pathology, Massachusetts General Hospital, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Hemminger","sequence":"additional","affiliation":[{"name":"Department of Pathology, Wexner Medical Center, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chang","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Johns Hopkins University School of Medicine, Baltimore, MD;"},{"name":"Institute for Clinical Research and Health Policy Studies and the Biostatistics, Epidemiology, and Research Design Center, Tufts Medical Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Kanakry","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Johns Hopkins University School of Medicine, Baltimore, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie H.","family":"Sehn","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Feldman","sequence":"additional","affiliation":[{"name":"Hackensack University Medical Center, Hackensack, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy S.","family":"Abramson","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology, Massachusetts General Hospital Cancer Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athena","family":"Kritharis","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology, Massachusetts General Hospital Cancer Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco J.","family":"Hernandez-Ilizaliturri","sequence":"additional","affiliation":[{"name":"Roswell Park Cancer Institute, Buffalo, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izidore S.","family":"Lossos","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Miami School of Medicine, Miami, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver W.","family":"Press","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Research Center, Seattle, WA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy S.","family":"Fenske","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Medical College of Wisconsin, Milwaukee, WI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, University of Rochester, Rochester, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie M.","family":"Vose","sequence":"additional","affiliation":[{"name":"University of Nebraska Medical Center, Omaha, NE;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristie A.","family":"Blum","sequence":"additional","affiliation":[{"name":"Division of Hematology, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Jagadeesh","sequence":"additional","affiliation":[{"name":"Cleveland Clinic, Cleveland, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Woda","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Massachusetts Medical School, Worcester, MA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav K.","family":"Gupta","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Tufts Medical Center, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy D.","family":"Gascoyne","sequence":"additional","affiliation":[{"name":"Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine S.","family":"Jaffe","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6900-1824","authenticated-orcid":false,"given":"Andrew M.","family":"Evens","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Tufts Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2017,12,11]]},"reference":[{"issue":"11","key":"2019111617081465800_B1","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1097\/01.pas.0000180856.74572.73","article-title":"Mediastinal gray zone lymphoma: the missing link between classic Hodgkin\u2019s lymphoma and mediastinal large B-cell lymphoma","volume":"29","author":"Traverse-Glehen","year":"2005","journal-title":"Am J Surg Pathol"},{"issue":"19","key":"2019111617081465800_B2","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","article-title":"The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications","volume":"117","author":"Campo","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2019111617081465800_B3","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s11899-011-0090-1","article-title":"Primary mediastinal large B-cell lymphoma, classic Hodgkin lymphoma presenting in the mediastinum, and mediastinal gray zone lymphoma: what is the oncologist to do?","volume":"6","author":"Grant","year":"2011","journal-title":"Curr Hematol Malig Rep"},{"issue":"1","key":"2019111617081465800_B4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2559.2005.02175.x","article-title":"Large B-cell lymphoma with Hodgkin\u2019s features","volume":"47","author":"Garc\u00eda","year":"2005","journal-title":"Histopathology"},{"issue":"9","key":"2019111617081465800_B5","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/ajh.24082","article-title":"Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort","volume":"90","author":"Evens","year":"2015","journal-title":"Am J Hematol"},{"issue":"suppl 4","key":"2019111617081465800_B6","doi-asserted-by":"crossref","first-page":"iv64","DOI":"10.1093\/annonc\/mdr178","article-title":"XII. Gray zone lymphomas: a biological experiment, and a challenge for diagnosis and management","volume":"22","author":"Eberle","year":"2011","journal-title":"Ann Oncol"},{"issue":"15","key":"2019111617081465800_B7","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1214561","article-title":"Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma","volume":"368","author":"Dunleavy","year":"2013","journal-title":"N Engl J Med"},{"key":"2019111617081465800_B8","article-title":"Untreated primary mediastinal B-cell (PMBL) and mediastinal grey zone (MGZL) lymphomas: comparison of biological features and clinical outcome following DA-EPOCH-R without radiation [abstract]","volume-title":"Ann Oncol","author":"Dunleavy","year":"2011"},{"issue":"1","key":"2019111617081465800_B9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2014-05-575092","article-title":"Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?","volume":"125","author":"Dunleavy","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2019111617081465800_B10","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/modpathol.2011.116","article-title":"Gray zone lymphoma: chromosomal aberrations with immunophenotypic and clinical correlations","volume":"24","author":"Eberle","year":"2011","journal-title":"Mod Pathol"},{"issue":"20","key":"2019111617081465800_B11","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"27","key":"2019111617081465800_B12","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"2019111617081465800_B13","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"2019111617081465800_B14","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observation","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"key":"2019111617081465800_B15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","article-title":"Regression models and life tables","volume":"34","author":"Cox","year":"1972","journal-title":"J R Stat Soc B"},{"issue":"4","key":"2019111617081465800_B16","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"2019111617081465800_B17","doi-asserted-by":"crossref","first-page":"587","DOI":"10.7326\/0003-4819-92-5-587","article-title":"Curability of advanced Hodgkin\u2019s disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute","volume":"92","author":"DeVita","year":"1980","journal-title":"Ann Intern Med"},{"issue":"3","key":"2019111617081465800_B18","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1200\/JCO.1986.4.3.284","article-title":"The pathologic and clinical heterogeneity of lymphocyte-depleted Hodgkin\u2019s disease","volume":"4","author":"Kant","year":"1986","journal-title":"J Clin Oncol"},{"issue":"Suppl 5","key":"2019111617081465800_B19","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1093\/annonc\/9.suppl_5.S31","article-title":"Workshop report on Hodgkin\u2019s disease and related diseases (\u2018grey zone\u2019 lymphoma)","volume":"9","author":"R\u00fcdiger","year":"1998","journal-title":"Ann Oncol"},{"issue":"4","key":"2019111617081465800_B20","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3324\/haematol.2010.033167","article-title":"Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin\u2019s lymphoma and primary mediastinal large B-cell lymphoma","volume":"96","author":"Eberle","year":"2011","journal-title":"Haematologica"},{"issue":"10","key":"2019111617081465800_B21","doi-asserted-by":"crossref","first-page":"4063","DOI":"10.1182\/blood-2002-05-1548","article-title":"Nodular sclerosing Hodgkin disease: new grading predicts prognosis in intermediate and advanced stages","volume":"101","author":"von Wasielewski","year":"2003","journal-title":"Blood"},{"issue":"6","key":"2019111617081465800_B22","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/1097-0142(19890315)63:6<1150::AID-CNCR2820630618>3.0.CO;2-4","article-title":"Grades of nodular sclerosis (NSI-NSII) in Hodgkin\u2019s disease. Are they of independent prognostic value?","volume":"63","author":"Wijlhuizen","year":"1989","journal-title":"Cancer"},{"issue":"2","key":"2019111617081465800_B23","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1046\/j.1365-2141.1997.d01-2010.x","article-title":"Disappearance of prognostic significance of histopathological grading of nodular sclerosing Hodgkin\u2019s disease for unselected patients, 1972-92","volume":"96","author":"van Spronsen","year":"1997","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111617081465800_B24","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/1097-0142(19930115)71:2<457::AID-CNCR2820710229>3.0.CO;2-U","article-title":"Hodgkin disease, nodular sclerosis type. Implications of histologic subclassification","volume":"71","author":"Ferry","year":"1993","journal-title":"Cancer"},{"issue":"6","key":"2019111617081465800_B25","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1084\/jem.20031074","article-title":"Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma","volume":"198","author":"Rosenwald","year":"2003","journal-title":"J Exp Med"},{"issue":"12","key":"2019111617081465800_B26","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1182\/blood-2003-06-1841","article-title":"The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma","volume":"102","author":"Savage","year":"2003","journal-title":"Blood"},{"issue":"7338","key":"2019111617081465800_B27","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","author":"Steidl","year":"2011","journal-title":"Nature"},{"issue":"10","key":"2019111617081465800_B28","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1182\/blood-2014-03-564906","article-title":"A prospective study of mediastinal gray-zone lymphoma","volume":"124","author":"Wilson","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2019111617081465800_B29","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3324\/haematol.2016.152256","article-title":"Mediastinal gray zone lymphoma: clinico-pathological characteristics and outcomes of 99 patients from the Lymphoma Study Association","volume":"102","author":"Sarkozy","year":"2017","journal-title":"Haematologica"},{"issue":"14","key":"2019111617081465800_B30","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1182\/blood-2012-10-461848","article-title":"CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"issue":"7","key":"2019111617081465800_B31","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1038\/modpathol.2012.52","article-title":"EBV-positive diffuse large B-cell lymphoma of the elderly is an aggressive post-germinal center B-cell neoplasm characterized by prominent nuclear factor-kB activation","volume":"25","author":"Montes-Moreno","year":"2012","journal-title":"Mod Pathol"},{"issue":"21","key":"2019111617081465800_B32","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","article-title":"A prognostic score for advanced Hodgkin\u2019s disease. International Prognostic Factors Project on Advanced Hodgkin\u2019s Disease","volume":"339","author":"Hasenclever","year":"1998","journal-title":"N Engl J Med"},{"issue":"5","key":"2019111617081465800_B33","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","article-title":"Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial","volume":"12","author":"Peyrade","year":"2011","journal-title":"Lancet Oncol"},{"issue":"2","key":"2019111617081465800_B34","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s12185-011-0898-4","article-title":"Primary mediastinal large B-cell lymphoma (PMLBCL) in Chinese patients: clinical characteristics and prognostic factors","volume":"94","author":"Zhu","year":"2011","journal-title":"Int J Hematol"},{"issue":"5","key":"2019111617081465800_B35","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/bjh.13486","article-title":"Prognostic model for mantle cell lymphoma in the rituximab era: a nationwide study in Japan","volume":"170","author":"Chihara","year":"2015","journal-title":"Br J Haematol"},{"issue":"9","key":"2019111617081465800_B36","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.3109\/10428194.2015.1010078","article-title":"A clinically based prognostic index for diffuse large B-cell lymphoma with a cut-off at 70 years of age significantly improves prognostic stratification: population-based analysis from the Danish Lymphoma Registry","volume":"56","author":"Gang","year":"2015","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2019111617081465800_B37","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s00277-016-2744-5","article-title":"Central nervous system relapse in patients with diffuse large B cell lymphoma: analysis of the risk factors and proposal of a new prognostic model","volume":"95","author":"Kanemasa","year":"2016","journal-title":"Ann Hematol"},{"issue":"2","key":"2019111617081465800_B38","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bjh.13116","article-title":"A modified scoring of the NCCN-IPI is more accurate in the elderly and is improved by albumin and \u03b22 -microglobulin","volume":"168","author":"Melchardt","year":"2015","journal-title":"Br J Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/26\/2600\/879962\/advances009472.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/1\/26\/2600\/879962\/advances009472.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T16:39:59Z","timestamp":1719679199000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/1\/26\/2600\/16257\/Clinicopathologic-consensus-study-of-gray-zone"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,11]]},"references-count":38,"journal-issue":{"issue":"26","published-print":{"date-parts":[[2017,12,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2017009472","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,11]]}}}